Anya BiopharmROCO:7776 12 EV-to-FCF is -16.83 as of Jul. 12, 2026. GuruFocus rates ROCO:7776 with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 329 Biotechnology companies, Anya Biopharm ranks worse than 303951.06% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Anya Biopharm's Enterprise Value is NT$1,193.63 Mil.
Anya Biopharm's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-70.92 Mil. Therefore, Anya Biopharm's EV-to-FCF for today is -16.83.
The historical rank and industry rank for Anya Biopharm's EV-to-FCF or its related term are showing as below:
ROCO:7776'
s EV-to-FCF Range Over the Past 10 Years
Min: -54.91 Med: -22.58 Max: -11.06
Current: -16.83
During the past 4 years, the highest EV-to-FCF of Anya Biopharm was -11.06. The lowest was -54.91. And the median was -22.58.
ROCO:7776's EV-to-FCF is ranked worse than 100% of 329
companies
in the Biotechnology industry
Industry Median: 15.85
vs ROCO:7776: -16.83
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Anya Biopharm's PE Ratio (TTM) for today is calculated as:
Anya Biopharm's share price for today is NT$31.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anya Biopharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1.300.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Anya Biopharm EV-to-FCF Related Terms
Anya Biopharm EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Anya Biopharm's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7776 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Anya Biopharm's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anya Biopharm EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anya Biopharm's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Anya Biopharm's EV-to-FCF falls into.
Anya Biopharm's current Enterprise Value is NT$1,193.63 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anya Biopharm's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-70.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anya Biopharm (ROCO:7776) has a EV-to-FCF of -16.83 as of Jul. 12, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Anya Biopharm and its competitors. According to the industry distribution chart, Anya Biopharm ranks #999999 out of 329 companies in the Biotechnology industry.
Is Anya Biopharm's EV-to-FCF too high?
Anya Biopharm's current EV-to-FCF is -16.83. Based on the distribution chart, Anya Biopharm ranks #999999 out of 329 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Anya Biopharm has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Anya Biopharm's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Anya Biopharm ranks #999999 out of 329 companies for EV-to-FCF. This places Anya Biopharm in the lower half of its industry. The industry median EV-to-FCF is 15.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.85, based on 329 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Anya Biopharm and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anya Biopharm's current EV-to-FCF is -16.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anya Biopharm stock overvalued right now?
Anya Biopharm (ROCO:7776) has a current EV-to-FCF of -16.83. The current EV-to-FCF is -16.83. Anya Biopharm's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Anya Biopharm (ROCO:7776), the current EV-to-FCF is -16.83 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anya Biopharm Inc is a pharmaceutical company engaged in the Oral Delivery of Peptides. Its patented technology platform Mira/Je is a flexible solution easy to adapt to a large variety of peptides.
12GF Score
Get the complete analysis for ROCO:7776
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7776 has been successfully added to your 